TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive NCI to Establish Three Grants Programs Supporting Clinical Cancer Research February 18, 1994
TCL Archive IL-2 Trials Proliferate; Biotherapeutics Sees NCI Proposal As Vindication Of Its Policies May 8, 1987
TCL Archive In Brief: Reauthorization Bill Could Go To House Floor Next Week; Packwood Blocks Action In Senate July 8, 1983
TCL Archive ODAC Votes For Approval Of PegIntron For Melanoma, Votrient For Renal Cancer October 9, 2009
